Efficacy of Subcutaneous Methylnaltrexone in the Treatment of Opioid-Induced Constipation: A Responder Post Hoc Analysis

Pain Medicine

Volumn 12, Issue 8, 2011, Pages 1223-1230

  Michna, Edward ^a   Weil, Arnold J ^b   Duerden, Marc ^c   Schulman, Seth ^d   Wang, Wenjin ^d   Tzanis, Evan ^d   Zhang, Haiying ^d   Yu, Dahong ^d   Manley, Amy ^d   Randazzo, Bruce ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Private Practice   (United States)

^c INDIANA UNIVERSITY   (United States)

^d PFIZER INC   (United States)

Author keywords

Constipation; Methylnaltrexone; Opioid Related Disorders; Opioids; Pain

Indexed keywords

17 METHYLNALTREXONE; OPIATE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; CHRONIC PAIN; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HOT FLUSH; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; TREATMENT RESPONSE;

EID: 80051675661     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01189.x     Document Type: Article

References (21)

1. Manchikanti L, Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008;11(suppl 2):S63-88.
2. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain. A randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
3. Watson CPN, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-8.
4. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain 2004;112:372-80.
5. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35:214-28.
6. Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G, MONTAS Study Group. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain-Results of a double-blind placebo-controlled trial (MONTAS). Pain 2002;97:223-33.
7. Roth SH, Fleischmann RM, Burch FX, etal. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain. Arch Intern Med 2000;160:853-60.
8. McNicol E, Horowicz-Mehler N, Fisk RA, etal. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain 2003;4:231-56.
9. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(suppl 5A):11S-8S.
10. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007;41:984-93.
11. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid investigational sites. J Pharmacol Exp Ther 1986;237:945-9.
12. Yuan CS, Doshan H, Charney MR, etal. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 2005;45:538-46.
13. Physician's Desk Reference, 63rd edition. Montvale, NJ: Thomsen Reuters; 2009.
14. Chamberlain BH, Cross K, Winston JL, etal. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage 2009;38:683-90.
15. Slatkin N, Thomas J, Lipman AG, etal. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009;7:39-46.
16. Thomas J, Karver S, Cooney GA, etal. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;328:2332-43.
17. Michna E, Blonsky ER, Schulman S, etal. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic nonmalignant pain: A randomized controlled study. J Pain 2011;12:554-62.
18. Bell TJ, Panchal SJ, Miaskowski C, etal. The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European patient survey (PROBE 1). Pain Med 2009;10:35-42.
19. Hill CS. Guidelines for Treatment of Cancer Pain. The Revised Pocket Edition of the Final Report of the Texas Cancer Council's Workgroup on Pain Control in Cancer Patients, 2nd edition. Austin, TX: Texas Cancer Council; 1997; Available at: (accessed June 2011).
20. Penning-van Beest FJ, van den Haak P, Klok RM, etal. Quality of life in relation to constipation among opioid users. J Med Econ 2010;13:129-35.
21. Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness-A cost-effectiveness analysis. Aliment Pharmacol Ther 2010;3:911-21.